Skip to main content

Main menu

  • Home
  • Our journals
    • Clinical Medicine
    • Future Healthcare Journal
  • Subject collections
  • About the RCP
  • Contact us

Clinical Medicine Journal

  • ClinMed Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Author guidance
    • Instructions for authors
    • Submit online
  • About ClinMed
    • Scope
    • Editorial board
    • Policies
    • Information for reviewers
    • Advertising

User menu

  • Log in

Search

  • Advanced search
RCP Journals
Home
  • Log in
  • Home
  • Our journals
    • Clinical Medicine
    • Future Healthcare Journal
  • Subject collections
  • About the RCP
  • Contact us
Advanced

Clinical Medicine Journal

clinmedicine Logo
  • ClinMed Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Author guidance
    • Instructions for authors
    • Submit online
  • About ClinMed
    • Scope
    • Editorial board
    • Policies
    • Information for reviewers
    • Advertising

Personalised medicine: using infliximab drug trough and anti-drug antibody levels improves clinical treatment decisions and is cost effective in spondyloarthritis and psoriatic arthritis

Sayam Dubash, Domini Bryer, Andrew Barr, John Fitton, Claire Wenham, Helena Marzo-Ortega and Jane Freeston
Download PDF
DOI: https://doi.org/10.7861/clinmedicine.19-2-s108
Clin Med March 2019
Sayam Dubash
ALeeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds
BNIHR Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Domini Bryer
ALeeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds
BNIHR Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew Barr
ALeeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds
BNIHR Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John Fitton
ALeeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds
BNIHR Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Claire Wenham
ALeeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds
BNIHR Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Helena Marzo-Ortega
ALeeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds
BNIHR Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jane Freeston
ALeeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds
BNIHR Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
Loading

Aims

Personalised medicine tailors treatment to the individual's needs. The advent of biosimilars has led to therapy re-appraisals driven by the clinical commissioning group's demand for cost-effective interventions. Yet biologic drug dosing is standardised and little is known about the rationale and efficacy of dose adjustment. As part of a service evaluation exercise within the Leeds Spondyloarthritis (SpA) Service, we measured serum drug trough levels (DLs) and anti-drug antibodies (ADAbs) in our cohort of SpA patients receiving bio-originator infliximab (Remicade) with the aims of a) informing our decision making before a possible switch to biosimilar and b) assessing the possible impact of this approach to our clinical practice.

Methods

Eligible patients were identified, counselled and consented by an experienced specialist nurse on DLs and ADAb testing including the possible associated outcomes such as a change in drug class, dose and infusion time interval. Subjects were also counselled on switching from bio-originator infliximab to the biosimilar infliximab CT-P13 (Infectra). We developed a treatment algorithm to act as a guide for the treating physician. Clinical and outcome data were recorded as per NHS practice including concomitant disease modifying anti-rheumatic drugs (DMARDs), disease status and the DLs and ADAb titre.

Results

A total of 35 subjects were identified. Infliximab was discontinued in two (6%) subjects, dose interval was extended in 6 (17%) and decreased in one (3%; Table 1⇓). The infliximab dose was reduced in two (6%) patients with no change in time interval. Two patients (6%) changed to an alternative biologic either within the same class or to a different mode of action due to persistent high disease activity on infliximab. ADAbs were absent in 14 of 16 (86%) subjects on concomitant methotrexate. Very high titre ADAbs were identified in four (11%) subjects with corresponding very low or undetectable DLs indicating a highly likely drug-neutralising effect. A total of 20 (57%) subjects were switched to a biosimilar. The total cost-savings were an added £25,720 per annum over the estimates for ‘blind’ switches of £34,000.

View this table:
  • View inline
  • View popup
Table 1.

Patient characteristics

View this table:
  • View inline
  • View popup
Table 2.

Results

Conclusion

These data from a small cohort suggest that measuring ADAbs and DLs to characterise treatment response and inform biosimilar switching is a clinically efficacious and cost-effective strategy in infliximab-treated SpA patients. We anticipate further significant savings with our cohort receiving subcutaneous therapies. This approach unlocks the potential of ‘personalised medicine’ which supports individualised treatment and brings significant savings to the NHS.

  • © Royal College of Physicians 2019. All rights reserved.
Back to top
Previous articleNext article

Article Tools

Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Personalised medicine: using infliximab drug trough and anti-drug antibody levels improves clinical treatment decisions and is cost effective in spondyloarthritis and psoriatic arthritis
Sayam Dubash, Domini Bryer, Andrew Barr, John Fitton, Claire Wenham, Helena Marzo-Ortega, Jane Freeston
Clinical Medicine Mar 2019, 19 (Suppl 2) 108-109; DOI: 10.7861/clinmedicine.19-2-s108

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Personalised medicine: using infliximab drug trough and anti-drug antibody levels improves clinical treatment decisions and is cost effective in spondyloarthritis and psoriatic arthritis
Sayam Dubash, Domini Bryer, Andrew Barr, John Fitton, Claire Wenham, Helena Marzo-Ortega, Jane Freeston
Clinical Medicine Mar 2019, 19 (Suppl 2) 108-109; DOI: 10.7861/clinmedicine.19-2-s108
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Aims
    • Methods
    • Results
    • Conclusion
  • Figures & Data
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Taking back control: a better deal for junior doctor engagement in rota design using e-Delphi and Assignment Problem Algorithm
  • Formation of a Junior Doctor Wellbeing Steering Group
  • Developing an acute oncology support smartphone app for Wales
Show more Research and innovation

Similar Articles

Navigate this Journal

  • Journal Home
  • Current Issue
  • Ahead of Print
  • Archive

Related Links

  • ClinMed - Home
  • FHJ - Home
clinmedicine Footer Logo
  • Home
  • Journals
  • Contact us
  • Advertise
HighWire Press, Inc.

Follow Us:

  • Follow HighWire Origins on Twitter
  • Visit HighWire Origins on Facebook

Copyright © 2021 by the Royal College of Physicians